<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR520.html">Part 520
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 520.1010  Furosemide.
                            </h3>
                            <p class="depth1"><em>(a)</em> Specifications. (1) Each tablet contains 12.5 or 50 milligrams (mg) furosemide.</p><p class="depth2"><em>(1)</em> Each tablet contains 12.5 or 50 milligrams (mg) furosemide.</p><p class="depth2"><em>(2)</em> Each bolus contains 2 grams (g) furosemide.</p><p class="depth2"><em>(3)</em> Each packet of powder contains 2 g furosemide.</p><p class="depth2"><em>(4)</em> Each milliliter of syrup contains 10 mg furosemide.</p><p class="depth1"><em>(b)</em> Sponsors. See sponsor numbers in Sec. 510.600(c) of this chapter for use of dosage forms and strengths listed in paragraph (a) of this section for uses as in paragraph (d) of this section.</p><p class="depth2"><em>(1)</em> No. 000010 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section.</p><p class="depth2"><em>(2)</em> No. 000061 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section; for boluses in paragraph (a)(2) of this section and powder in paragraph (a)(3) of this section for conditions of use in paragraph (d)(1) of this section; and for syrup in paragraph (a)(4) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(A).</p><p class="depth2"><em>(3)</em> Nos. 000859 and 058829 for use of syrup in paragraph (a)(4) of this section for conditions of use in paragraph (d)(2)(i) and (d)(2)(ii)(A) of this section.</p><p class="depth1"><em>(c)</em> Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth1"><em>(d)</em> Conditions of use. It is used as follows:</p><p class="depth2"><em>(1)</em> Cattle--(i) Amount. 1 to 2 mg per pound (/lb) body weight using powder, or one 2-g bolus per animal, per day.</p><p class="depth3"><em>(i)</em> Amount. 1 to 2 mg per pound (/lb) body weight using powder, or one 2-g bolus per animal, per day.</p><p class="depth3"><em>(ii)</em> Indications for use. For treatment of physiological parturient edema of the mammary gland and associated structures.</p><p class="depth3"><em>(iii)</em> Limitations. Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.</p><p class="depth2"><em>(2)</em> Dogs--(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.</p><p class="depth3"><em>(i)</em> Amount. 1 to 2 mg/lb body weight, once or twice daily.</p><p class="depth3"><em>(ii)</em> Indications for use--(A) For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.</p><p class="depth4"><em>(A)</em> For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.</p><p class="depth4"><em>(B)</em> For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency.</p><p class="depth2"><em>(3)</em> Cats--(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.</p><p class="depth3"><em>(i)</em> Amount. 1 to 2 mg/lb body weight, once or twice daily.</p><p class="depth3"><em>(ii)</em> Indications for use. For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.
[66 FR 47960, Sept. 17, 2001, as amended at 69 FR 74419, Dec. 14, 2004; 70 FR 50182, Aug. 26, 2005; 70 FR 76396, Dec. 27, 2005; 74 FR 61516, Nov. 25, 2009; 78 FR 17596, Mar. 22, 2013]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
